Research programme: IL-17/IL-23 bispecific antibody - Bristol-Myers Squibb
Alternative Names: IL-17/IL-23 biAbLatest Information Update: 16 Jul 2016
At a glance
- Originator Bristol-Myers Squibb
- Class Bispecific antibodies
- Mechanism of Action Interleukin 17 modulators; Interleukin 23 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Immunological-disorders in USA (Parenteral)
- 31 Dec 2012 Preclinical trials in Immunological disorders in USA (Parenteral)